investment solidifies its Rahway HQs role as global R&D hub Read full article: #Merck #ResearchAndDevelopment #RahwayNJ #LifeSciences #HealthcareInnovation #BiotechIndustry #GlobalRAndD #Pharmaceuticals To view or add a comment, sign in Understanding the Difference Between Me-too Drugs and Generics In the pharmaceutical world, innovation and accessibility often go hand in hand
Expect the usual suspects performance, beauty, hangover relief, immunity, and energy with some drips available in both liter and half-liter amounts
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
So, their long-term safety remains unknown
doi.org/10.1111/j.1749-6632.2010.05492.x Bock-Marquette, I., et al
